White Diamond Research says Pulse Biosciences (PLSE)’ Nano-Pulse Stimulation technology “has a long history of commercial failures which contradict the company’s sky-high valuation of $1B+.” In a research report posted on its website, White Diamond argues Pulse’s new application in benign thyroids will be “another dead end.” The company’s “history of failure will likely continue,” the firm contends.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: